United States - English - NLM (National Library of Medicine)

bi-coastal pharmaceutical corporation - isoxsuprine hydrochloride (unii: v74teq36co) (isoxsuprine - unii:r15ui3245n) - isoxsuprine hydrochloride 10 mg - based on a review of this drug by the national academy of sciences-national research and/or other information, the fda has classified the indications as follows: - for the relief of symptoms associated with cerebrovascular insufficiency. - in peripheral vascular disease of arteriosclerosis obliterans, thromboangitis obliterans (buerger's disease) and raynaud's disease. final classification of the less-than-effective indications requires further investigation. there are no known contraindications to oral use when administered in recommended doses. isoxsuprine hydrochloride, usp should not be given immediately postpartum or in the presence of arterial bleeding.

United States - English - NLM (National Library of Medicine)

bi-coastal pharma international limited liability company - isoxsuprine hydrochloride (unii: v74teq36co) (isoxsuprine - unii:r15ui3245n) - isoxsuprine hydrochloride 10 mg - based on a review of this drug by the national academy of sciences-national research and/or other information, the fda has classified the indications as follows: - for the relief of symptoms associated with cerebrovascular insufficiency. - in peripheral vascular disease of arteriosclerosis obliterans, thromboangitis obliterans (buerger's disease) and raynaud's disease. final classification of the less-than-effective indications requires further investigation. there are no known contraindications to oral use when administered in recommended doses. isoxsuprine hydrochloride, usp should not be given immediately postpartum or in the presence of arterial bleeding.

United States - English - NLM (National Library of Medicine)

attix pharmaceuticals - isoxsuprine hydrochloride (unii: v74teq36co) (isoxsuprine - unii:r15ui3245n) - isoxsuprine hydrochloride 5 kg in 5 kg

United States - English - NLM (National Library of Medicine)

vedco dba valdar - isoxsuprine hydrochloride (unii: v74teq36co) (isoxsuprine - unii:r15ui3245n) - based on a review of this drug by the national academy of sciences-national research and/or other information, the fda has classified the indications as follows: - for the relief of symptoms associated with cerebrovascular insufficiency. - in peripheral vascular disease of arteriosclerosis obliterans, thromboangitis obliterans (buerger's disease) and raynaud's disease. final classification of the less-than-effective indications requires further investigation. there are no known contraindications to oral use when administered in recommended doses. isoxsuprine hydrochloride, usp should not be given immediately postpartum or in the presence of arterial bleeding.

United States - English - NLM (National Library of Medicine)

eci pharmaceuticals llc - isoxsuprine hydrochloride (unii: v74teq36co) (isoxsuprine - unii:r15ui3245n) - based on a review of this drug by the national academy of sciences-national research and/or other information, the fda has classified the indications as follows: - for the relief of symptoms associated with cerebrovascular insufficiency. - in peripheral vascular disease of arteriosclerosis obliterans, thromboangitis obliterans (buerger's disease) and raynaud's disease. final classification of the less-than-effective indications requires further investigation. there are no known contraindications to oral use when administered in recommended doses. isoxsuprine hydrochloride, usp should not be given immediately postpartum or in the presence of arterial bleeding.

United States - English - NLM (National Library of Medicine)

syntho pharmaceuticals inc. - isoxsuprine hydrochloride (unii: v74teq36co) (isoxsuprine - unii:r15ui3245n) - based on a review of this drug by the national academy of sciences-national research and/or other information, the fda has classified the indications as follows: possibly effective: - for the relief of symptoms associated with cerebrovascular insufficiency. - in peripheral vascular disease of arteriosclerosis obliterans, thromboangitis obliterans (buerger's disease) and raynaud's disease. final classification of the less-than-effective indications requires further investigation. there are no known contraindications to oral use when administered in recommended doses. isoxsuprine hydrochloride, usp should not be given immediately postpartum or in the presence of arterial bleeding.

United States - English - NLM (National Library of Medicine)

syntho pharmaceuticals inc. - isoxsuprine hydrochloride (unii: v74teq36co) (isoxsuprine - unii:r15ui3245n) - based on a review of this drug by the national academy of sciences-national research and/or other information, the fda has classified the indications as follows: possibly effective: - for the relief of symptoms associated with cerebrovascular insufficiency. - in peripheral vascular disease of arteriosclerosis obliterans, thromboangitis obliterans (buerger's disease) and raynaud's disease. final classification of the less-than-effective indications requires further investigation. there are no known contraindications to oral use when administered in recommended doses. isoxsuprine hydrochloride, usp should not be given immediately postpartum or in the presence of arterial bleeding.

United States - English - NLM (National Library of Medicine)

vista pharmaceuticals, inc. - isoxsuprine hydrochloride (unii: v74teq36co) (isoxsuprine - unii:r15ui3245n) - based on a review of this drug by the national academy of sciences -national research council and / or other information, the fda has classified the medications as follows : possibly effective : 1. for the relief of symptoms associated with cerebral vascular insufficiency 2. in peripheral vascular disease of arteriosclerosis obliterans, thromboangitis obliterans (buerger's disease) and raynaud's disease. final classification of the less-than-effective indications requires further investigation. oral there are no known contraindications to oral use when administered in recommended doses. should not be given immediately postpartum or in the presence of arterial bleeding.

United States - English - NLM (National Library of Medicine)

kalchem international inc - isoxsuprine hydrochloride (unii: v74teq36co) (isoxsuprine hydrochloride - unii:v74teq36co) -

United States - English - NLM (National Library of Medicine)

letco medical, llc - isoxsuprine hydrochloride (unii: v74teq36co) (isoxsuprine hydrochloride - unii:v74teq36co) -